Clinical Trial: Prevention of Drug Rash From Certain Cancer Therapies Using Tretinoin Cream

Study Status: Withdrawn
Recruit Status: Withdrawn
Study Type: Interventional

Official Title: Prevention of Epidermal Growth Factor Receptor Inhibitor-Associated Dermatologic Toxicities by Pre-treatment With Topical Tretinoin

Brief Summary:

This research is being done to study whether using of topical tretinoin can help prevent the common rash that patients often get while taking epidermal growth factor inhibitor (EGFR-I) medications such ascetuximab or erlotinib.

Patients taking EGFR-I medications often develop skin irritation and acne-like bumps on their face, chest, and other areas. This rash from EGFR-I's is often treated with moisturizers and topical or oral antibiotics. However, there has not yet been a study looking at a way to prevent this common side effect from occurring, and topical tretinoin may be useful in reducing the rash.

Tretinoin 0.025% cream is approved by the Food and Drug Administration (FDA) for the treatment of acne, acne scarring, and photodamage. It is not approved for use in preventing rashes associated with EGFR-I's.

Detailed Summary:
Sponsor: Johns Hopkins University

Current Primary Outcome: EGFRi rash severity [ Time Frame: 8 weeks ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Johns Hopkins University

Dates:
Date Received: May 5, 2011
Date Started: May 2011
Date Completion:
Last Updated: April 21, 2014
Last Verified: April 2014